Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited
- Market cap
- $2.07B
Your view on RGC
Overview
What the company does, where it operates, and who runs it.
About Regencell Bioscience Holdings Limited
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Yat-Gai Au
- Headquarters
- First Commercial Building, Causeway Bay, HK
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Yat-Gai Au
- Headquarters
- First Commercial Building, Causeway Bay, HK
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.
The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Regencell Bioscience Holdings Limited. Starting points for Regencell Bioscience Holdings Limited: EPS -$0.02, beta 1.43 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Regencell Bioscience Holdings Limited. Trailing twelve-month EPS for Regencell Bioscience Holdings Limited stands at -$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Hold
Analyst ratings
4 ratings- Strong Buy0
- Buy0
- Hold4
- Sell0
- Strong Sell0
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Regencell Bioscience Holdings Limited. Regencell Bioscience Holdings Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals, Inc. | Healthcare | Biotechnology | $3.3B | ||
| AXSMAxsome Therapeutics, Inc. | Healthcare | Biotechnology | $6.8B | ||
| HRMYHarmony Biosciences Holdings, Inc. | Healthcare | Biotechnology | $1.9B | ||
| LBRXLB Pharmaceuticals Inc Common Stock | Healthcare | Biotechnology | $1.3B | ||
| PRAXPraxis Precision Medicines, Inc. | Healthcare | Biotechnology | $8.4B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ACB.TOAurora Cannabis Inc. | Healthcare | TSX | $393.8M | ||
| ACURAcura Pharmaceuticals, Inc. | Healthcare | OTC | $33,001 | ||
| ACUSAcusphere, Inc. | Healthcare | OTC | $49 | ||
| AFP.AXAFT Pharmaceuticals Limited | Healthcare | ASX | — | ||
| AGFAFDigicann Ventures Inc. | Healthcare | OTC | $606,354 | ||
| AGYTFAllergy Therapeutics plc | Healthcare | OTC | $504.6M | ||
| AIDAAida Pharmaceuticals, Inc. | Healthcare | OTC | $8,101 | ||
| AKANAkanda Corp. | Healthcare | NASDAQ | $10.1M | ||
| ALGWFAlliance Growers Corp. | Healthcare | OTC | — | ||
| ALIDAllied Corp. | Healthcare | OTC | $57,748 | ||
| ALKSAlkermes plc | Healthcare | NASDAQ | $7.6B | ||
| ALVOAlvotech | Healthcare | NASDAQ | $1.5B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| ONEQFIDELITY NASDAQ COMPOSITE INDEX ETF | $10.4B in assets | 0.01% | |
| GXCState Street SPDR S&P China ETF | $441M in assets | 0.00% | |
Largest holders first, then the funds most concentrated in RGC.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Regencell Bioscience Holdings Limited, and how their positions are changing. At a $2.07B market value, institutional positions materially move Regencell Bioscience Holdings Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Regencell Bioscience Holdings Limited executives and directors. Shares of Regencell Bioscience Holdings Limited have traded between $0.09 and $83.60 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Regencell Bioscience Holdings Limited. Regencell Bioscience Holdings Limited is a $2.07B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Regencell Bioscience Holdings Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Regencell Bioscience Holdings Limited. Coverage tracks Regencell Bioscience Holdings Limited within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Regencell Bioscience Holdings Limited.